Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

@article{Huarte2008DepletionOD,
  title={Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.},
  author={Eduardo Huarte and Juan R Cubillos-Ruiz and Yolanda C. Nesbeth and Uciane K. Scarlett and Diana G Martinez and Ronald J. Buckanovich and Fabi{\'a}n Benencia and Radu V Stan and Tibor Keler and Pablo Sarobe and Charles L. Sentman and Jos{\'e} Ram{\'o}n Conejo-Garcia},
  journal={Cancer research},
  year={2008},
  volume={68 18},
  pages={7684-91}
}
Dendritic cells (DC) and cytokines that expand myeloid progenitors are widely used to treat cancer. Here, we show that CD11c(+)DEC205(+) DCs coexpressing alpha-smooth muscle actin and VE-cadherin home to perivascular areas in the ovarian cancer microenvironment and are required for the maintenance of tumor vasculature. Consequently, depletion of DCs in mice bearing established ovarian cancer by targeting different specific markers significantly delays tumor growth and enhances the effect of… CONTINUE READING